SCHEMBL5964584

SCHEMBL5964584

CN(Cc1ccc(-c2ccccc2C(F)(F)F)cc1F)CC(O)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 1/20 0.71
▸ S1PR1 P21453 3/20 0.42
▸ ALOX5AP P20292 1/20 0.39
▸ FEN1 P39748 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ FAAH O00519 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ AKR1C3 P42330 2/20 0.38
▸ AKR1C2 P52895 2/20 0.38
▸ AOC3 Q16853 1/20 0.37
▸ USP2 O75604 2/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ TSHR P16473 2/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5964318 0.92 CNR2 (0.60) CNR2S1PR1ALOX5APFEN1KDM4E
SCHEMBL5964191 0.88 CNR2 (0.54) CNR2S1PR1ALOX5APFEN1FAAH
SCHEMBL5963869 0.83 CNR2 (1.00) CNR2S1PR1KDM4EMEN1KMT2A
SCHEMBL5963872 0.83 CNR2 (1.00) CNR2S1PR1KDM4EMEN1KMT2A
SCHEMBL5964304 0.83 CNR2 (1.00) CNR2S1PR1KDM4EMEN1KMT2A
SCHEMBL5964494 0.79 KMT2A (0.45) CNR2S1PR1ALOX5APFEN1MEN1
SCHEMBL6209365 0.77 CNR2 (0.43) CNR2S1PR1ALOX5APFEN1KDM4E
SCHEMBL5964586 0.76 FAAH (0.45) CNR2ALOX5APFEN1KDM4ESMN1; SMN2
SCHEMBL6194878 0.75 CNR2 (0.77) CNR2S1PR1KDM4EMEN1KMT2A
SCHEMBL5964676 0.75 CNR2 (0.83) CNR2KDM4EMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060052315-A1 Cb 1/cb 2 receptor ligands and their use in the treatment of pain ASTRAZENECA AB (SE) 2006-03-09 — — US claimed
EP-1594856-A1 CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN AstraZeneca AB (SE) 2005-11-16 — — EP claimed
WO-2004060882-A1 CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2004-07-22 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052315-A1 Cb 1/cb 2 receptor ligands and their use in the treatment of pain CNR1, CNR2, OPRL1 CNR2 2/4885S1PR1 474/4885ALOX5AP 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback